Manufacturing, Biologics

Scorpius Holdings to Launch Mammalian CGMP Manufacturing Campaign at Texas Site

July 26, 2024

Scorpius Holdings expects to launch its first CGMP campaign for mammalian-based biomanufacturing in the 2024 third quarter.

BeiGene Launches Biologics Manufacturing and Clinical R&D Facility in New Jersey

July 25, 2024

BeiGene has invested $800 million into a new biologics manufacturing facility in Hopewell, NJ, which also houses its clinical R&D capabilities.

Ecolab Life Sciences and Repligen Launch New Affinity Resin for Commercial Biologics Manufacturing

June 13, 2024

Ecolab Life Sciences and Repligen introduce DurA Cycle, a new affinity resin for large-scale biologics manufacturing.

Syngene Launches Rapid Protein Synthesis Platform

June 12, 2024

Syngene has launched a new protein production platform that offers faster production with lower risk.

AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site

June 11, 2024

AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.

Innovations in Prefilled Biologics

June 07, 2024

Packaging and packaging line innovations are addressing the industry’s growing use of biologics.

Increased Capacity Needed for Mammalian Cell Culture (BIO 2024)

June 07, 2024

FUJIFILM Diosynth Biotechnologies CEO Lars Petersen highlights the company’s strategic goals and meeting market demand for mammalian cell culture capacity.

BIO 2024: Finding a More Optimal Way for ATMPs

June 05, 2024

Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.

BIO 2024: Exploring the Potential of mRNA

June 04, 2024

Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.

BIO 2024: Seeking Excellence with CRISPR

June 04, 2024

BioPharm International chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.